Summary of COVID-19 olokizumab studies

1. Samsonov et al., An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)

372 patient olokizumab late treatment RCT: 50% higher mortality (p=0.6) and 30% greater improvement (p=0.21).
RCT 248 hospitalized patients showing no significant differences with olokuzimab.
Jan 2022, NCT04380519, https://clinicaltrials.gov/study/NCT04380519, https://c19p.org/samsonovokz